GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Belluscura PLC (FRA:9VQ) » Definitions » Stock Based Compensation

Belluscura (FRA:9VQ) Stock Based Compensation : €0.18 Mil (TTM As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Belluscura Stock Based Compensation?

Belluscura's Stock Based Compensation for the six months ended in Jun. 2023 was €0.09 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2023 was €0.18 Mil.


Belluscura Stock Based Compensation Historical Data

The historical data trend for Belluscura's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belluscura Stock Based Compensation Chart

Belluscura Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Stock Based Compensation
- 0.01 0.09 0.16 0.22

Belluscura Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only 0.13 0.02 0.13 0.09 0.09

Belluscura Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.18 Mil.


Belluscura Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Belluscura's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Belluscura (FRA:9VQ) Business Description

Traded in Other Exchanges
Address
15 Fetter Lane, Holborn, London, GBR, EC4A 1BW
Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.

Belluscura (FRA:9VQ) Headlines

No Headlines